Arctic Bioscience AS (OSL:ABS)

Market Cap	85.72M +21.8%
Revenue (ttm)	42.62M -4.0%
Net Income	-41.03M
EPS	-1.52
Shares Out	26.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,877
Open	3.450
Previous Close	3.180
Day's Range	3.160 - 3.450
52-Week Range	2.820 - 4.800
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 19
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2025, Arctic Bioscience AS's revenue was 42.62 million, a decrease of -4.00% compared to the previous year's 44.39 million. Losses were -41.03 million, -14.41% less than in 2024.